Orion OYJ (OTCMKTS:ORINY) Shares Gap Down – Here’s What Happened
by Danessa Lincoln · The Markets DailyOrion OYJ Unsponsored ADR (OTCMKTS:ORINY – Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $39.13, but opened at $36.15. Orion OYJ shares last traded at $36.15, with a volume of 130 shares.
Wall Street Analyst Weigh In
Separately, Nordea Equity Research upgraded Orion OYJ from a “hold” rating to a “buy” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Check Out Our Latest Research Report on Orion OYJ
Orion OYJ Trading Down 7.6%
The business’s 50 day simple moving average is $34.89 and its 200-day simple moving average is $37.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.99 and a quick ratio of 1.19. The stock has a market capitalization of $10.20 billion, a P/E ratio of 29.15 and a beta of 0.05.
Orion OYJ (OTCMKTS:ORINY – Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $0.40 earnings per share for the quarter. Orion OYJ had a return on equity of 31.36% and a net margin of 19.33%.The company had revenue of $494.69 million for the quarter. As a group, analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current year.
About Orion OYJ
Orion Corporation (Orion Oyj) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.
Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France.